Los puntos clave no están disponibles para este artículo en este momento.
Effective longitudinal biomarkers that track disease progression are needed to characterize the presymptomatic phase of genetic frontotemporal dementia (FTD). We investigate the utility of cerebral perfusion as one such biomarker in presymptomatic FTD mutation carriers.
Pasternak et al. (2024) studied this question.